$Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients$

Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients

Abstract Introduction The off-label use of TNF antagonists in refractory sarcoidosis is increasingly reported but data on their efficacy and safety are still insufficient. Objective To report on efficacy and safety of TNF antagonists in severe and refractory sarcoidosis. Methods Examination of retro...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Seminars in Arthritis and Rheumatism 2017-10, Vol.47 (2), p.288-294
Hauptverfasser:	Jamilloux, Yvan, MD, Cohen-aubart, Fleur, MD, PhD, Chapelon-abric, Catherine, MD, Maucort-boulch, Delphine, MD, PhD, Marquet, Alicia, MD, Pérard, Laurent, MD, Bouillet, Laurence, MD, PhD, Deroux, Alban, MD, Abad, Sébastien, MD, PhD, Bielefeld, Philip, MD, Bouvry, Diane, MD, André, Marc, MD, PhD, Noel, Nicolas, MD, Bienvenu, Boris, MD, PhD, Proux, Alice, MD, Vukusic, Sandra, MD, PhD, Bodaghi, Bahram, MD, PhD, Sarrot-reynauld, Françoise, MD, PhD, Iwaz, Jean, PhD, Amoura, Zahir, MD, PhD, Broussolle, Christiane, MD, Cacoub, Patrice, MD, PhD, Saadoun, David, MD, PhD, Valeyre, Dominique, MD, PhD, Sève, Pascal, MD, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Efficacy Female Humans Immunology Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Infliximab - adverse effects Infliximab - therapeutic use Life Sciences Male Middle Aged Retrospective Studies Rheumatology Safety Sarcoidosis Sarcoidosis - drug therapy TNF antagonist Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Introduction The off-label use of TNF antagonists in refractory sarcoidosis is increasingly reported but data on their efficacy and safety are still insufficient. Objective To report on efficacy and safety of TNF antagonists in severe and refractory sarcoidosis. Methods Examination of retrospective demographic, clinical, therapeutic, and adverse event data on 132 sarcoidosis patients (58% women; mean (min-max) age 45.5 (14–78) years) given TNF antagonists (mainly infliximab, 91%) and investigation of response-linked factors. Results The overall clinical response (complete and partial) rate was 64%. TNF-antagonist efficacy (i.e., significant decrease of the ePOST score) was noted in cases with neurologic, heart, skin, and upper respiratory tract involvements. No significant difference in efficacy was found between anti-TNF used alone and TNF with immunosuppressant. The use of anti-TNF allowed reducing prednisone dosage at end of follow-up (p
ISSN:	0049-0172 1532-866X
DOI:	10.1016/j.semarthrit.2017.03.005